E
Erasca
A San Diego based biotechnology company focused on discovering and developing precision medicines for the benefit of patients with cancer
About Erasca
Erasca is a clinical-stage precision oncology company with a mission to eradicate cancer. The company's primary focus is on shutting down the RAS/MAPK pathway, a commonly mutated signaling cascade in cancer that affects approximately 5.5 million lives globally each year. By targeting this pathway, Erasca aims to make a significant difference in the treatment of various devastating cancers.
Read full description
The company's business model revolves around the development and commercialization of a robust pipeline of therapeutic programs. These programs are designed to comprehensively shut down the RAS/MAPK pathway, regardless of the modality. This approach could potentially transform the lives of millions of cancer patients, offering them hope for a brighter, cancer-free future.
Erasca was co-founded in July 2018 by Jonathan Lim, a physician-turned-venturepreneur. Jonathan has a track record of founding, funding, and leading biotechnology companies that have achieved global regulatory approval and launched several therapeutic products in oncology, immunology, and drug delivery. These products have benefitted thousands of patients worldwide and generated approximately $10 billion of shareholder value.
Erasca operates in the global oncology market, serving a wide range of clients, including healthcare providers and cancer patients. The company generates revenue through the development, approval, and commercialization of its therapeutic products.
At a glance
- Founded
- 2018
- Headquarters
- San Diego, United States
- Listing
- IPO 2021
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Latest news
Press, funding announcements and product moves mentioning Erasca.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A12 investors entered at this stage
City Hill Ventures
Cormorant Asset Management
Andreessen Horowitz- RMReneo Capital Management
ARCH Venture Partners
EDBI
LifeSci Venture Partners
Invus
Colt Ventures- TPTerra Magnum Capital Partners
OrbiMed
PFM Health Sciences
Series B and later7 investors entered at this stage
- EDEDBI
- LPLifeSci Venture Partners
- INInvus
- TPTerra Magnum Capital Partners
- PSPFM Health Sciences
- OrbiMed
- CVColt Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
20 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Erasca on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Erasca on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.